# Atea (AVIR) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/AVIR
## Company Profile
- Ticker: AVIR
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Infectious Disease
## Stock Data
- Close: 4.99 USD
- Market cap: 341715712.72999996 USD
- Last updated: 2026-08-06
## Business Overview
### Antiviral Therapeutics Company
Atea Pharmaceuticals develops oral antiviral combinations for serious viral diseases.
### Hepatitis C Regimen
The lead regimen combines nucleotide polymerase inhibitor bemnifosbuvir with NS5A inhibitor ruzasvir as a short-duration, ribavirin-free treatment for hepatitis C.
### Global Phase 3 Program
C-BEYOND covers North America, while C-FORWARD evaluates the same regimen outside North America.
### Hepatitis E Pipeline
AT-587 is an earlier oral candidate being developed as a potential first-in-class treatment for hepatitis E.
## Why The Stock Is Moving

The latest company update was “Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026”. AVIR changed 1.06% and closed at $4.75 on Aug 5, 2026, indicating a relatively limited closing-price reaction to this earnings update.

## Future Catalysts

- Topline results from the Phase 3 C-BEYOND hepatitis C study are expected in mid-2026.
- C-FORWARD enrollment is expected to complete in mid-2026, with topline results around year-end 2026.
- A Phase 1 study of AT-587 in hepatitis E is expected to begin around mid-2026.

## Recent News
- 2026-08-05 11:00 EST — [Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-to-host-second-quarter-2026-financial-results-and-business--3cfcfb78) — Source: Atea
- 2026-07-28 11:00 EST — [Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-meets-both-its-primary-and-secondary-endpoints-in-the-phase-d04e8293) — Source: Atea
- 2026-07-14 11:00 EST — [Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-initiates-first-in-human-phase-1-clinical-trial-of-at-587-f-8ed8b55f) — Source: Atea
- 2026-06-25 11:00 EST — [Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-completes-patient-enrollment-in-phase-3-c-forward-trial-eva-825c5ef5) — Source: Atea
- 2026-05-27 11:00 EST — [Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-presents-new-drug-drug-interaction-results-supporting-potential-best-in-class-profile-of-the-regimen-of-bemnifosbuvir-and-ruzasvir-for-the-treatment-of-hepatitis-c-virus-at-easl-congress-2026) — Source: Atea